The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Systematic review of influenza resistance to the neuraminidase inhibitors
Open accessAbstract
BACKGROUND: Antivirals play a critical role in the prevention and the management of influenza. One class of antivirals, neuraminidase inhibitors (NAIs), is effective against all human influenza viruses. Currently there are two NAI drugs which are licensed worldwide: oseltamivir (Tamiflu®) and zanamivir (Relenza®); and two drugs which have received recent approval in Japan: peramivir and laninamivir. Until recently, the prevalence of antiviral resistance has been relatively low. However, almost all seasonal H1N1 strains that circulated in 2008-09 were resistant to oseltamivir whereas about 1% of tested 2009 pandemic H1N1 viruses were found to be resistant to oseltamivir. To date, no studies have demonstrated widespread resistance to zanamivir. It seems likely that the literature on antiviral resistance associated with oseltamivir as well as zanamivir is now sufficiently comprehensive to warrant a systematic review.The primary objectives were to systematically review the literature to determine the incidence of resistance to oseltamivir, zanamivir, and peramivir in different population groups as well as assess the clinical consequences of antiviral resistance. METHODS: We searched MEDLINE and EMBASE without language restrictions in September 2010 to identify studies reporting incidence of resistance to oseltamivir, zanamivir, and peramivir. We used forest plots and meta-analysis of incidence of antiviral resistance associated with the three NAIs. Subgroup analyses were done across a number of population groups. Meta-analysis was also performed to evaluate associations between antiviral resistance and clinical complications and symptoms. RESULTS: We identified 19 studies reporting incidence of antiviral resistance. Meta-analysis of 15 studies yielded a pooled incidence rate for oseltamivir resistance of 2.6% (95%CI 0.7% to 5.5%). The incidence rate for all zanamivir resistance studies was 0%. Only one study measured incidence of antiviral resistance among subjects given peramivir and was reported to be 0%. Subgroup analyses detected higher incidence rates among influenza A patients, especially for H1N1 subtype influenza. Considerable heterogeneity between studies precluded definite inferences about subgroup results for immunocompromised patients, in-patients, and children. A meta-analysis of 4 studies reporting association between oseltamivir-resistance and pneumonia yielded a statistically significant risk ratio of 4.2 (95% CI 1.3 to 13.1, p = 0.02). Oseltamivir-resistance was not statistically significantly associated with other clinical complications and symptoms. CONCLUSION: Our results demonstrate that that a substantial number of patients may become oseltamivir-resistant as a result of oseltamivir use, and that oseltamivir resistance may be significantly associated with pneumonia. In contrast, zanamivir resistance has been rarely reported to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538 · cited 1×
“For the RCTs, we assessed the adequacy of the methods used for randomization, allocation concealment, blinding, and follow-up [22,23].”
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Cited by
Influenza virus-induced lung injury: pathogenesis and implications for treatment
Herold, S., Becker, C., Ridge, K. M., & Budinger, G. R. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186214 · Cited by 503
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
Self-citationInfluenza and antiviral resistance: an overview
Lampejo, T. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03840-9 · Cited by 342
Inhibition of sialidase activity as a therapeutic approach
Glanz, V. Y., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s176220 · Cited by 59
Metadata
- Authors
- Thorlund, K., Awad, T., Boivin, G., & Thabane, L.
- Venue
- BMC Infectious Diseases
- Published
- 2011-05-19
- Volume
- 11
- Issue
- 1
- Pages
- 134-134
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2008617110
- Cited by
- 189
- References
- 2
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review of influenza resistance to the neuraminidase inhibitors. https://app.cochat.ai/papers/10.1186/1471-2334-11-134
- The paper
- Thorlund, K., Awad, T., Boivin, G., & Thabane, L. (2011). Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-11-134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.